THE COST OF STAGE IV MELANOMA WITH BRAF V600 MUTATIONS IN GREECE

被引：0
|
作者：
Carayanni, V [1 ]
Gogas, H. [2 ]
Bafaloukos, D. [3 ]
Boukovinas, I [4 ]
Latsou, D. [5 ]
Stamuli, E. [5 ]
Hatzikou, M. [5 ]
机构：
[1] Univ Western Attica, Alimos, Greece
[2] Natl & Kapodistrian Univ Athens, Athens, Greece
[3] Metropolitan Hosp, Athens, Greece
[4] Bioclin Oncol Unit Thessaloniki, Thessaloniki, Greece
[5] Pharmecons Easy Access, Varkiza, Greece
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN222
引用
收藏
页码：S462 / S462
页数：1
相关论文
共 50 条
  • [41] BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay
    Michiko Tatsuno
    Yoko Shioda
    Hideto Iwafuchi
    Shigeki Yamazaki
    Kenta Iijima
    Chiaki Takahashi
    Hiromi Ono
    Kiyono Uchida
    Osamu Okamura
    Mamoru Matubayashi
    Torayuki Okuyama
    Kimikazu Matsumoto
    Takako Yoshioka
    Atsuko Nakazawa
    Diagnostic Pathology, 11
  • [42] Validation of a Laboratory Developed Test (LDT) for the Detection of BRAF V600 Mutations for Therapeutic Decision Making in Melanoma Patients
    Dumur, C. I.
    Idowu, M. O.
    Almenara, J. A.
    Wilkinson, D. S.
    Ferreira-Gonzalez, A.
    Powers, C. N.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2012, 14 (06): : 721 - 721
  • [43] Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma
    Czarnecka, Anna M.
    Ostaszewski, Krzysztof
    Borkowska, Aneta
    Szumera-Cieckiewicz, Anna
    Kozak, Katarzyna
    Switaj, Tomasz
    Rogala, Pawel
    Kalinowska, Iwona
    Kosela-Paterczyk, Hanna
    Zaborowski, Konrad
    Teterycz, Pawel
    Tysarowski, Andrzej
    Makula, Donata
    Rutkowski, Piotr
    CANCERS, 2022, 14 (01)
  • [44] Quantitative assessment of BRAF V600 mutant cell-free tumor DNA from plasma as a diagnostic and therapeutic biomarker in pts with BRAF V600 mutant melanoma
    Schreuer, Max
    Meersseman, Geert
    Jansen, Yanina
    Seremet, Teofila
    Chevolet, Ines
    Bott, Ambre
    Wilgenhof, Sofie
    Maertens, Geert
    Neyns, Bart
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Use of Cobas 4800 BRAF mutation test for the analysis of BRAF V600 mutations in cytological samples (CS) from metastatic melanoma (MM)
    Martin-Algarra, Salvador
    Labiano, Tania
    Ignacio Echeveste, Jose
    Gomez, Nerea
    Montanana, Myriam
    Aguirre, Mercedes
    Eugenia Echarri, Maria
    Sanmamed, Miguel F.
    Gurpide, Alfonso
    Luis Perez-Gracia, Jose
    Idoate, Miguel A.
    Lozano, Maria D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] VEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION
    Haanen, J. B. A. G.
    Scholtens, A.
    Geukes, M.
    van Thienen, H.
    van Tinteren, H.
    ANNALS OF ONCOLOGY, 2014, 25
  • [47] Intrapatient homogeneity of BRAF V600 status in melanoma with the exception of sentinel lymph node
    Nardin, C.
    Puzenat, E.
    Doussot, A.
    Pretet, J. L.
    Algros, M. P.
    Deveza, E.
    Adotevi, O.
    Aubin, F.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB171 - AB171
  • [48] The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence
    Lemech, Charlotte
    Infante, Jeffrey
    Arkenau, Hendrik-Tobias
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2012, 4 (02) : 61 - 73
  • [49] Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression
    Scholtens, A.
    Foppen, M. H. Geukes
    Blank, C. U.
    van Thienen, J. V.
    van Tinteren, H.
    Haanen, J. B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (05) : 642 - 652
  • [50] BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods
    O'Brien, Odharnaith
    Lyons, Tomas
    Murphy, Sandra
    Feeley, Linda
    Power, Derek
    Heffron, Cynthia C. B. B.
    JOURNAL OF CLINICAL PATHOLOGY, 2017, 70 (11) : 935 - 940
12345